Company Overview

Evaxion Biotech A/S, commonly referred to as Evaxion A/S and publicly traded on Nasdaq under the ticker EVAX, is a Denmark-based biotechnology company focused on the development of AI-powered immunotherapies and vaccines. The company operates within the biotechnology, oncology, and infectious disease sectors, using proprietary artificial intelligence platforms to identify and design therapeutic vaccine candidates. Its primary revenue sources historically have included research collaborations, grant funding, and capital raised through public markets, as the company remains in the clinical development stage and does not yet report material commercial product sales.

Evaxion’s core business centers on individualized and precision-based immunotherapies, particularly cancer vaccines targeting neoantigens and bacterial disease prevention technologies. The company’s proprietary AI platforms include PIONEER, EDEN, and RAVEN, which are designed to predict clinically relevant antigens and optimize vaccine development. Founded in Denmark in 2008, Evaxion evolved from an AI-focused biotechnology research company into a clinical-stage immunotherapy developer with multiple oncology and infectious disease programs. The company has positioned itself around the combination of machine learning and immunology, seeking to shorten vaccine discovery timelines and improve treatment specificity.

Business Operations

Evaxion conducts operations primarily through integrated biotechnology research and clinical development activities. Its principal business areas include oncology vaccine programs, bacterial infectious disease vaccines, and AI-driven immunology discovery services. The company’s oncology pipeline has included candidates such as EVX-01 and EVX-02, targeting metastatic melanoma and other cancers through personalized neoantigen vaccines, while infectious disease efforts have focused on combating antimicrobial resistance through bacterial antigen prediction technologies. Revenue generation remains primarily tied to strategic collaborations, licensing opportunities, grants, and financing activities rather than product commercialization.

The company operates primarily from Denmark while maintaining relationships with clinical trial partners, contract research organizations, and pharmaceutical collaborators internationally. Evaxion controls several proprietary AI and bioinformatics technologies that form the basis of its intellectual property portfolio and clinical pipeline. Strategic partnerships have included collaborations with pharmaceutical and biotechnology entities focused on immuno-oncology and vaccine development, although the scope and duration of individual partnerships have varied over time. Public disclosures indicate that the company continues to invest heavily in research and development relative to its size and stage of commercialization.

Strategic Position & Investments

Evaxion’s strategic direction centers on expanding the clinical validation of its AI-driven vaccine platforms and advancing oncology immunotherapy candidates through clinical trials. The company has emphasized precision medicine approaches, particularly personalized cancer vaccines tailored to patient-specific neoantigens. Its broader strategy also includes leveraging machine learning to address infectious diseases and antimicrobial resistance, areas increasingly prioritized by global healthcare systems and regulators. Management has consistently communicated an objective of partnering or licensing successful vaccine programs to larger pharmaceutical companies capable of supporting later-stage development and commercialization.

The company has invested substantially in its proprietary AI infrastructure and immunology datasets, which it identifies as a competitive differentiator. Evaxion has also pursued non-dilutive funding opportunities through research grants and collaborative arrangements. While the company does not maintain a broad portfolio of independently operated subsidiaries comparable to larger pharmaceutical firms, its platform-based structure functions as a portfolio of internally developed technology engines supporting multiple therapeutic applications. Public filings and investor communications indicate continued focus on emerging sectors such as AI-enabled drug discovery, personalized oncology, and next-generation vaccine development.

Geographic Footprint

Evaxion is headquartered in Hørsholm, Denmark, and its operational footprint is concentrated primarily in Europe and North America through clinical activities, investor engagement, and collaboration networks. The company’s shares trade on the Nasdaq Capital Market in the United States, providing access to U.S. biotechnology investors and capital markets despite its Danish operational base. Clinical development activities have involved partnerships and trial sites across multiple countries depending on the specific study program.

The company’s market presence remains relatively limited compared with multinational pharmaceutical companies, reflecting its status as a clinical-stage biotechnology enterprise. Nevertheless, Evaxion’s technology platforms and therapeutic focus areas position it within globally relevant healthcare markets, particularly immuno-oncology and infectious disease prevention. Its international influence is primarily derived from scientific collaborations, regulatory engagement, and participation in global biotechnology investment markets rather than large-scale commercial operations.

Leadership & Governance

Evaxion was founded by scientists and biotechnology entrepreneurs seeking to apply artificial intelligence and computational biology to vaccine development. The company is governed through a board structure consistent with Danish corporate governance standards and U.S. public market requirements following its Nasdaq listing. Leadership communications have emphasized data-driven drug development, platform scalability, and the integration of AI into precision immunotherapy research.

Key executives and leadership figures include:

• Christian Kanstrup – Chief Executive Officer
• Birgitte Rønø – Chief Scientific Officer
• Per Norlén – Chairman of the Board
• Mikkel Wandahl Pedersen – Chief Technology Officer
• Jakob Schmidt – Chief Financial Officer

Management has consistently articulated a strategic vision focused on validating AI as a commercially viable biotechnology development tool while advancing differentiated immunotherapies in oncology and infectious disease markets. Certain executive roles and organizational structures have changed periodically, and investors are advised to consult the company’s most recent SEC filings and annual reports for the latest governance information.